Literature DB >> 16618242

Accessing health outcome data on high-cost medicines in Australia.

Christine Y Lu1, Kenneth M Williams, Richard O Day.   

Abstract

Data on health outcomes resulting from the use of medicines provide important evidence of cost-effectiveness. Currently, clinical information on individual patients, collected by Medicare Australia to assess eligibility for subsidised treatment with high-cost medicines, is inaccessible for research. Comprehensive data on drug use and health outcomes should be made accessible, with appropriate regulation, so that the effectiveness, utility and appropriateness of our systems of access to medicines can be independently analysed. In the interests of continuous improvement in medical care and optimal use of limited resources, we strongly advocate the enhancement of Medicare Australia databases and liberalisation of arrangements for access to administrative and clinical data.

Entities:  

Mesh:

Year:  2006        PMID: 16618242     DOI: 10.5694/j.1326-5377.2006.tb00293.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01

2.  Patient access schemes in Asia-pacific markets: current experience and future potential.

Authors:  Christine Y Lu; Caitlin Lupton; Shana Rakowsky; Zaheer-Ud-Din Babar; Dennis Ross-Degnan; Anita K Wagner
Journal:  J Pharm Policy Pract       Date:  2015-02-16

3.  Access to high cost medicines in Australia: ethical perspectives.

Authors:  Christine Y Lu; Paul Macneill; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2008-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.